Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

ClinicalTrials.gov ID: NCT06088043

Public ClinicalTrials.gov record NCT06088043. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 3:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 61 weeks.

Study identification

NCT ID
NCT06088043
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Takeda
Industry
Enrollment
693 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 5, 2023
Primary completion
Jan 21, 2025
Completion
Oct 21, 2025
Last update posted
Oct 23, 2025

2023 – 2025

United States locations

U.S. sites
27
U.S. states
17
U.S. cities
27
Facility City State ZIP Site status
Saguaro Dermatology Associates, LLC - Probity - PPDS Phoenix Arizona 85008-3884
First OC Dermatology - Fountain Valley Fountain Valley California 92708-3701
Center for Dermatology Clinical Research Fremont California 94538-1614
UCLA University of California Los Angeles Los Angeles California 90024
UC Davis Dermatology Clinic Sacramento California 95816-3370
Driven Research LLC Coral Gables Florida 33134-3901
FXM Clinical Research Ft. Lauderdale, LLC Fort Lauderdale Florida 33308-5211
Direct Helpers Research Center Hialeah Florida 33012-3618
FXM Clinical Research Miami, LLC Miami Florida 33175-3582
Renstar Medical Research -21 NE 1st Ave Ocala Florida 34470-6657
Marietta Dermatology & The Skin Cancer Center - Marietta Marietta Georgia 30060-7902
Leavitt Clinical Research - 1542 Elk Creek Dr Idaho Falls Idaho 83404-8322
Arlington Dermatology Rolling Meadows Illinois 60008-3811
Dawes Fretzin Clinical Research Group-7910 N Shadeland Ave Indianapolis Indiana 46256-4697
Kindred Hair & Skin Center - CAR Columbia Maryland 21046-1246
Revival Research Corporation - Michigan - ClinEdge - PPDS Troy Michigan 48084-3536
Grekin Skin Institute Warren Michigan 48088-3671
Henderson Clinical Trials Henderson Nevada 89052-5016
Dartmouth Hitchcock Medical Center Lebanon New Hampshire 03766-1937
ALLCUTIS Research, LLC. Portsmouth New Hampshire 03801-6822
Northwell Health Physician Partners Dermatology at Lake Success - BRANY - PPDS New York New York 10003-3314
Accellacare of Cary Cary North Carolina 27518-7414
Bexley Dermatology Research - Probity - PPDS Bexley Ohio 43209
Clinical Research Center of the Carolinas, LLC Charleston South Carolina 29407-5347
International Clinical Research-Tennessee LLC Murfreesboro Tennessee 37130-2450
Bellaire Dermatology Associates Bellaire Texas 77401-3505
Progressive Clinical Research PA - San Antonio San Antonio Texas 78213-2250

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06088043, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 23, 2025 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06088043 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →